BTK and diffuse large B-cell lymphoma: Interestingly, BTK inhibitors did not display a clear benefit for long-term survival in PT-DLBCL patients, which may be due to their use primarily in the relapsed/refractory (R/R) setting rather than as part of frontline therapy.